Apellis Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q1 2016 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Apellis Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2016 to Q4 2024.
  • Apellis Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$26.2M, a 69% increase year-over-year.
  • Apellis Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$165M, a 68.1% increase year-over-year.
  • Apellis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$165M, a 68.1% increase from 2023.
  • Apellis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$517M, a 13% increase from 2022.
  • Apellis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$595M, a 10.9% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$165M -$26.2M +$58.4M +69% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-28
Q3 2024 -$223M -$47.3M +$89.8M +65.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$313M -$29.4M +$91M +75.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$404M -$62.1M +$113M +64.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$517M -$84.5M +$79.5M +48.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-28
Q3 2023 -$597M -$137M +$15.9M +10.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$613M -$120M +$28.2M +19% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$641M -$175M -$46.1M -35.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$595M -$164M -$74.6M -83.5% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-28
Q3 2022 -$520M -$153M -$24.9M -19.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$495M -$149M +$45.7M +23.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-07-31
Q1 2022 -$541M -$129M -$4.41M -3.54% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$536M -$89.4M -$220M -169% Oct 1, 2021 Dec 31, 2021 10-K/A 2024-02-29
Q3 2021 -$317M -$128M +$1.56M +1.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$318M -$194M -$78.8M -68.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$240M -$125M -$25.8M -26.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$214M $130M +$236M Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$450M -$130M -$59.6M -85.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$390M -$116M -$52M -82% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$338M -$98.8M -$50.1M -103% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 -$288M -$106M -$68.7M -185% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$219M -$69.9M -$34.1M -95.4% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$185M -$63.5M -$30M -89.6% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$155M -$48.7M -$27.2M -127% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$128M -$37.2M -$19.2M -107% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$109M -$35.8M -$24.2M -209% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$84.5M -$33.5M -$21.4M -176% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$63.2M -$21.4M -$12.4M -137% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$50.8M -$18M -$11.7M -188% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-26
Q3 2017 -$39M -$11.6M -$4.36M -60.2% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-26
Q2 2017 -$34.7M -$12.1M -$4.56M -60.2% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-26
Q1 2017 -$30.1M -$9.05M -$2.82M -45.3% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-26
Q4 2016 -$27.3M -$6.25M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-19
Q3 2016 -$7.23M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-19
Q2 2016 -$7.57M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-19
Q1 2016 -$6.23M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.